Crizotinib
Nov. 25, 2024
FDA approves crizotinib for ALK-positive inflammatory myofibroblastic tumor — ALK POSITIVE Crizotinib hydrochloride | ≥99%(HPLC) | Selleck | c-Met 阻害剤 Crizotinib (PF-02341066) | ALK/c-Met/ROS1 Inhibitor | MedChemExpress Crizotinib